AACE / ACE Ενημερωμένος Αλγόριθμος για το Διαβήτη τύπου 2 – 2020

Ενημερωμένη έκδοση 2020 της διαχείρισης του ΣΔ τ2 από τις επιστημονικές εταιρείες American Association of Clinical Endocrinologists (AACE) και American College of Endocrinology (ACE).

Επιλογή από τις ενημερώσεις:

… New guidance for primary and secondary prevention of CVD, strokes, congestive heart failure (CHF), chronic kidney disease (CKD), and mortality are independent of patient lipid and glucose levels, given that SGLT2 inhibitors and long-acting GLP1 receptor agonists with proven benefits may be prescribed as first line in these patients. (υπογράμμιση χρώματος από το spikar.gr, δείτε την εικόνα που ακολουθεί) Additional new guidance includes: Management of patients who have moderate to severe CKD (e.g., an eGFR ≥30 mL/min/1.73m2) with SGLT2 inhibitors that have shown benefit, specifically canagliflozin. Management of patients with CHF with reduced function with SGLT2i with proven benefit, specifically dapagliflozin. Management of patients with established or high risk for CVD who have triglyceride levels between 135-499 mg/dL with EPA with proven benefits to prevent the next event …

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY
Download »»

⇒ Από τον server spikar.gr (ταχεία μεταφόρτωση) »»